Cellectar Biosciences Inc's stock surged by 16.56% as it crossed above the 5-day SMA, reflecting positive investor sentiment.
The company announced plans to submit a Conditional Marketing Authorization application for iopofosine I 131 to the EMA in 3Q 2026, which could significantly expand its market share in WM treatment across approximately 30 countries. Additionally, Cellectar is preparing to initiate a Phase 1b study for CLR 125 in triple-negative breast cancer, with interim data expected in mid-2026, further enhancing its clinical pipeline. The company also raised $15.2 million to support these initiatives, boosting investor confidence.
This strategic move positions Cellectar favorably in the competitive biopharmaceutical landscape, potentially leading to increased market presence and investor interest as it showcases its advancements at the upcoming Biotech Showcase.
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
